4142:TPE
Adimmune Corp
NT$16.35
arrow_downward
-1.51%(-0.25) 1D
Nov 6, 1:30:04 PM GMT+8 · TWD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4142...
Open
NT$16.05
High
NT$16.50
Low
NT$15.65
Mkt. cap
7.02B
Avg. vol.
1.08M
Volume
2.16M
52-wk high
NT$22.50
52-wk low
NT$15.65
EPS
-NT$0.34
Shares outstanding
235.29M
No. of employees
564
Open
NT$16.05
High
NT$16.50
Low
NT$15.65
Mkt. cap
7.02B
Avg. vol.
1.08M
Volume
2.16M
52-wk high
NT$22.50
52-wk low
NT$15.65
EPS
-NT$0.34
Shares outstanding
235.29M
No. of employees
564
News stories
From web sources and news partners
Benzinga
·
1 hour ago
Dow Jones and S&P 500 Outlook: Stock Market News To Watch This Week
The Motley Fool
·
3 hours ago
No Matter What Happens to the S&P 500 in November, These 3 Dividend Stocks Belong in Your Portfolio
BigGo Finance
·
15 hours ago
Global AI and Semiconductor Stocks Plunge; S&P 500 Tumbles 4.4% in a Single Day as Markets Watch Whether Three Central Banks Will Raise Rates in December
Exchange Rates UK
·
29 minutes ago
S&P 500 Slide Exposes Large Stock Moves Hidden Beneath The Index
Profile
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
About Adimmune Corp
CEO-
Employees564
Founded1965
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteadimmune.com.tw